Valion Bio Inc (VBIO) Stock Price, Quote & News

Company Profile

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, In...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 276 6888

Website: tivichealth.com

Address:

1305 E. Houston Street, Suite 311, Building 1, San Antonio, United States

NEWBIGTECH Jun. 6 at 3:45 PM

$VBIO

0 · Reply

jpurr Jun. 5 at 8:56 PM

$VBIO How big will the RS be?

1 · Reply

topstockalerts Jun. 5 at 2:24 AM

$VBIO there’s a certain stubbornness to this strength.

0 · Reply

PapaRoki Jun. 4 at 9:55 PM

$VBIO what a beauty

0 · Reply

sandman7473 Jun. 4 at 9:15 PM

$VBIO ah

0 · Reply

ChartChartist Jun. 4 at 9:08 PM

$VBIO do it

0 · Reply

urgetosurge Jun. 3 at 8:24 PM

$VBIO book value 3.84

1 · Reply

urgetosurge Jun. 3 at 7:58 PM

$VBIO approx 5.8 million shares outstanding and 3.5 mc. Watchers dropped to 93. Under the radar bigly.

1 · Reply

urgetosurge Jun. 3 at 4:49 PM

$VBIO 8k filed. All approved. https://www.otcmarkets.com/filing/html?id=19509334&guid=XjC-kq67dusRdth

1 · Reply

Insdr Jun. 3 at 1:10 PM

$VBIO Their NIAID grant (announced in May 2026) will fully support their BLA-enabling studies to the tune of $7 Million; they had $7.2 M in cash at the end of March; and they are in advanced negotiation stages for either a BARDA or BAA contract, yet their Mkt Cap is $2.3 Million? Yeah, I'm loading up. GLTA

0 · Reply

Valion Bio Transcript: AGM 2026

May 19, 2026, 4:38 PM EDT - 20 days ago

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

2026-05-14T22:26:28.000Z - 25 days ago

Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform

2026-05-14T21:41:38.000Z - 25 days ago

Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year

May 14, 2026, 4:31 PM EDT - 25 days ago

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

May 14, 2026, 4:30 PM EDT - 25 days ago

Valion Bio Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 25 days ago

Valion Bio Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 25 days ago

Valion Bio Quarterly report: Q1 2026

May 14, 2026, 4:05 PM EDT - 25 days ago

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

May 11, 2026, 8:01 AM EDT - 4 weeks ago

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

May 6, 2026, 8:08 AM EDT - 4 weeks ago

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

2026-05-05T12:15:18.000Z - 4 weeks ago

Valion Bio receives first study protocol under agreement with NIAID

May 5, 2026, 8:00 AM EDT - 4 weeks ago

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

2026-05-04T20:42:49.000Z - 5 weeks ago

Valion Bio names Melinda Lackey as General Counsel

TCRT

May 4, 2026, 4:05 PM EDT - 5 weeks ago

Valion Bio Appoints Melinda Lackey as General Counsel

TCRT

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Valion Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:01 AM EDT - 5 weeks ago

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Apr 23, 2026, 4:05 PM EDT - 6 weeks ago

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Valion Bio Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Valion Bio Registration statement: Registration filing

Apr 1, 2026, 2:55 PM EDT - 2 months ago

Valion Bio Transcript: Emerging Growth Conference 91

Mar 31, 2026, 8:30 AM EDT - 2 months ago

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Mar 27, 2026, 11:30 AM EDT - 2 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

Mar 26, 2026, 8:30 AM EDT - 2 months ago

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Valion Bio Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Valion Bio Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Valion Bio Earnings release: Q4 2025

Mar 25, 2026, 4:05 PM EDT - 2 months ago

Tivic Reports Full Year 2025 Results

Mar 24, 2026, 9:30 AM EDT - 2 months ago

Tivic Health CEO Letter to Shareholders

Mar 20, 2026, 3:35 PM EDT - 2 months ago

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Mar 12, 2026, 4:00 PM EDT - 3 months ago

Valion Bio Transcript: EGM 2026

Mar 4, 2026, 8:30 AM EST - 3 months ago

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Mar 4, 2026, 6:00 AM EST - 3 months ago

Valion Bio Slides: Investor presentation

Feb 18, 2026, 9:15 AM EST - 3 months ago

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Feb 9, 2026, 7:00 AM EST - 4 months ago

Valion Bio Proxy statement: Proxy Filing

Jan 28, 2026, 8:30 AM EST - 4 months ago

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Jan 26, 2026, 10:10 AM EST - 4 months ago

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Jan 22, 2026, 4:10 PM EST - 4 months ago

Valion Bio Transcript: Emerging Growth Conference 89

Jan 20, 2026, 5:50 PM EST - 4 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Jan 20, 2026, 7:00 AM EST - 4 months ago

Valion Bio Slides: Investor presentation

Jan 12, 2026, 4:30 PM EST - 5 months ago

Valion Bio Transcript: Investor Update

Jan 12, 2026, 9:00 AM EST - 5 months ago

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

Jan 9, 2026, 7:00 AM EST - 5 months ago

Valion Bio Proxy statement: Proxy Filing

Jan 8, 2026, 8:30 AM EST - 5 months ago

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

Dec 29, 2025, 7:00 AM EST - 5 months ago

Valion Bio Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 5 months ago

Valion Bio Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 5 months ago

Valion Bio Proxy statement: Proxy Filing

Dec 11, 2025, 9:45 AM EST - 6 months ago

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

Nov 18, 2025, 8:30 AM EST - 7 months ago

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Nov 14, 2025, 4:30 PM EST - 7 months ago

Tivic Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:30 PM EST - 7 months ago

Valion Bio Earnings Call Transcript: Q3 2025

Nov 14, 2025, 4:30 PM EST - 7 months ago

Valion Bio Quarterly report: Q3 2025

Nov 14, 2025, 4:30 PM EST - 7 months ago

Valion Bio Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 7 months ago

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

Nov 10, 2025, 9:00 AM EST - 7 months ago

Tivic Expands Intellectual Property Portfolio

Nov 6, 2025, 9:30 AM EST - 7 months ago

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

Oct 22, 2025, 2:00 PM EDT - 8 months ago

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Valion Bio Registration statement: Registration Filing

Sep 25, 2025, 11:25 AM EDT - 9 months ago

Valion Bio Transcript: Emerging Growth Conference 2025

Sep 22, 2025, 8:30 AM EDT - 9 months ago

Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference

Sep 10, 2025, 8:30 AM EDT - 9 months ago

Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

Aug 29, 2025, 8:00 AM EDT - 10 months ago

Valion Bio Registration statement: Registration Filing

Aug 20, 2025, 8:30 AM EDT - 10 months ago

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Aug 15, 2025, 8:30 AM EDT - 10 months ago

Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Valion Bio Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Valion Bio Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Valion Bio Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Tivic Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Valion Bio Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Valion Bio Registration statement: Registration Filing

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Valion Bio Registration statement: Registration Filing

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Announces 2025 Annual Meeting of Stockholders

Jun 11, 2025, 1:30 PM EDT - 1 year ago

Valion Bio Transcript: Life Sciences Virtual Investor Forum

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Proxy statement: Proxy Filing

May 22, 2025, 1:00 PM EDT - 1 year ago

Valion Bio Transcript: Sidoti May Micro-Cap Virtual Conference

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

May 14, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

May 13, 2025, 8:30 AM EDT - 1 year ago

Tivic Expands VNS Intellectual Property Portfolio

May 9, 2025, 8:30 AM EDT - 1 year ago

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

May 9, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

Apr 10, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q4 2024

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Annual report: Q4 2024

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings release: Q4 2024

Mar 21, 2025, 4:00 PM EDT - 1 year ago

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Mar 13, 2025, 4:59 PM EDT - 1 year ago

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

Mar 6, 2025, 8:15 AM EST - 1 year ago

Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

Mar 5, 2025, 8:15 AM EST - 1 year ago

Tivic Health Systems, Inc. Announces Reverse Stock Split

NEWBIGTECH Jun. 6 at 3:45 PM

$VBIO

0 · Reply

jpurr Jun. 5 at 8:56 PM

$VBIO How big will the RS be?

1 · Reply

topstockalerts Jun. 5 at 2:24 AM

$VBIO there’s a certain stubbornness to this strength.

0 · Reply

PapaRoki Jun. 4 at 9:55 PM

$VBIO what a beauty

0 · Reply

sandman7473 Jun. 4 at 9:15 PM

$VBIO ah

0 · Reply

ChartChartist Jun. 4 at 9:08 PM

$VBIO do it

0 · Reply

urgetosurge Jun. 3 at 8:24 PM

$VBIO book value 3.84

1 · Reply

urgetosurge Jun. 3 at 7:58 PM

$VBIO approx 5.8 million shares outstanding and 3.5 mc. Watchers dropped to 93. Under the radar bigly.

1 · Reply

urgetosurge Jun. 3 at 4:49 PM

$VBIO 8k filed. All approved. https://www.otcmarkets.com/filing/html?id=19509334&guid=XjC-kq67dusRdth

1 · Reply

Insdr Jun. 3 at 1:10 PM

0 · Reply

YoloAlfred May. 29 at 9:37 PM

$VBIO Peter that one will also be a winner

0 · Reply

YoloAlfred May. 29 at 9:02 PM

$VBIO yes....

0 · Reply

IWinYouWinWeWin May. 29 at 3:07 PM

$VBIO $7.2 million in cash and cash equivalents as of March 31, 2026.

0 · Reply

Espre May. 29 at 8:39 AM

$VBIO no one attended the meeting? What was the outcome? Filing and replay are not uploaded yet…

1 · Reply

urgetosurge May. 28 at 8:41 PM

$VBIO can't say I'm surprised. 2.5 mc. I'll add on the capitulation wash out. Last post until a clear bottom reversal.

0 · Reply

Nakuldesai May. 28 at 8:11 PM

$VBIO waiting for bankruptcy on this one.

0 · Reply

Espre May. 28 at 6:28 PM

$VBIO news?

0 · Reply

urgetosurge May. 28 at 1:27 PM

$VBIO the big question here is have we reached bottom??

0 · Reply

Nakuldesai May. 26 at 1:52 PM

$VBIO this stock will get delisted. The company is run by a bunch of idiots.

0 · Reply

Espre May. 25 at 8:13 AM

$VBIO 3 days until the shareholder meeting(may 28th)

0 · Reply

urgetosurge May. 22 at 9:15 AM

$VBIO 2.8 million market cap. Outstanding increased to 3.2 million. Corporate continues to dilute.

1 · Reply

IWinYouWinWeWin May. 21 at 6:27 PM

$VBIO glad I added 5k more this morning!

0 · Reply

Market Cap	2.43M
Revenue (ttm)	0.00
Net Income (ttm)	-8.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.27

Volume	36,200
Avg Vol	190,766
Day's Range	N/A - N/A
Shares Out	3.20M
Stochastic %K	59%
Beta	1.79
Analysts	Strong Buy
Price Target	$3.50